Clinical Trial Update: Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation [Phase 2]

View source ↗

Summary

Phase 2 trial update on CBP-201 for moderate to severe persistent asthma with Type 2 inflammation reports efficacy and safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• To Severe Persistent Asthma

Drugs mentioned

• CBP-201

Snippet

Sponsor: Connect Biopharm LLC | Conditions: Moderate to Severe Persistent Asthma | Phase 2 | Status: COMPLETED